Evolus (EOLS) Receivables - Other (2017 - 2018)

Evolus (EOLS) reported Receivables - Other of $100000.0 for Q1 2018, down 99.86% quarter-over-quarter from $72.6 million in Q4 2017.

Evolus (EOLS) Receivables - Other (2017 - 2018) Analysis & Trends

Evolus has reported Receivables - Other for 2 years, with the latest figure at $100000.0 in Q1 2018.

For the quarter ending Q1 2018, Receivables - Other changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Mar 2018 stood at $100000.0 (changed N/A YoY), and the FY2017 full-year result was $72.6 million, changed N/A from the prior year.
Receivables - Other for Q1 2018 stood at $100000.0, down from $72.6 million in the prior quarter.
The five-year high for Receivables - Other was $72.6 million in Q4 2017, with the low at $100000.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn
10	Evolus	435.45 Mn	385.65 Mn	48.90 Mn

Download Data